
## Xercavins, J

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8687574/publications.pdf Version: 2024-02-01



YEDCAMINE 1

#	Article	IF	CITATIONS
1	Molecular diagnosis of endometrial cancer from uterine aspirates. International Journal of Cancer, 2013, 133, 2383-2391.	2.3	15
2	Prediction of non-sentinel lymph node metastasis in early breast cancer by assessing total tumoral load in the sentinel lymph node by molecular assay. European Journal of Surgical Oncology, 2013, 39, 766-773.	0.5	50
3	The EMT signaling pathways in endometrial carcinoma. Clinical and Translational Oncology, 2012, 14, 715-720.	1.2	95
4	Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease. Molecular and Cellular Endocrinology, 2012, 358, 244-255.	1.6	54
5	Location of aortic node metastases in locally advanced cervical cancer. Gynecologic Oncology, 2012, 125, 312-314.	0.6	37
6	Generation and characterization of orthotopic murine models for endometrial cancer. Clinical and Experimental Metastasis, 2012, 29, 217-227.	1.7	26
7	Breast conservative surgery after neoadjuvant chemotherapy in breast cancer patients: Comparison of two tumor localization methods. European Journal of Surgical Oncology, 2011, 37, 1038-1043.	0.5	17
8	Molecular markers of endometrial carcinoma detected in uterine aspirates. International Journal of Cancer, 2011, 129, 2435-2444.	2.3	105
9	Can we predict local recurrence in breast conserving surgery after neoadjuvant chemotherapy?. European Journal of Surgical Oncology, 2010, 36, 528-534.	0.5	23
10	Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress. Carcinogenesis, 2009, 30, 1288-1297.	1.3	50
11	An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasis. International Journal of Cancer, 2009, 125, 257-263.	2.3	44
12	Subtractive Proteomic Approach to the Endometrial Carcinoma Invasion Front. Journal of Proteome Research, 2009, 8, 4676-4684.	1.8	22
13	Removal of all radioactive sentinel nodes in breast cancer improves the detection of positive sentinel nodes. Clinical and Translational Oncology, 2008, 10, 347-350.	1.2	3
14	Novel molecular profiles of endometrial cancer—new light through old windows. Journal of Steroid Biochemistry and Molecular Biology, 2008, 108, 221-229.	1.2	188
15	ERM/ETV5 Up-regulation Plays a Role during Myometrial Infiltration through Matrix Metalloproteinase-2 Activation in Endometrial Cancer. Cancer Research, 2007, 67, 6753-6759.	0.4	57
16	Sentinel lymph node identification in a primary ductal carcinoma arising in the vulva. International Journal of Gynecological Cancer, 2007, 17, 471-477.	1.2	11
17	Molecular determinants of invasion in endometrial cancer. Clinical and Translational Oncology, 2007, 9, 272-277.	1.2	37
18	The up-regulation profiles of p21WAF1/CIP1 and RUNX1/AML1 correlate with myometrial infiltration in endometrioid endometrial carcinomaã~†. Human Pathology, 2006, 37, 1050-1057.	1.1	22

Xercavins, J

#	Article	IF	CITATIONS
19	Extraperitoneal laparoscopic para-aortic lymphadenectomy for lymph node recurrence of fallopian tube carcinoma. International Journal of Gynecological Cancer, 2006, 16, 991-993.	1.2	5
20	Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors. Histology and Histopathology, 2006, 21, 197-204.	0.5	44
21	Usefulness of sentinel lymph node detection in early stages of cervical cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1210-1216.	3.3	32
22	Clinicopathologic Features and Genetic Alterations in Endometrioid Carcinoma of the Uterus with Villoglandular Differentiation. American Journal of Clinical Pathology, 1999, 111, 336-342.	0.4	46
23	Advances in the molecular genetics of endometrial cancer (Review) Oncology Reports, 1999, 6, 1377-82.	1.2	27
24	Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis, 1997, 18, 2307-2311.	1.3	136
25	Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1) Tj ETQq1 1 (	).784314 2.9	rgBT /Overic
26	Merkel Cell Carcinoma of the Vulva. Gynecologic Oncology, 1997, 64, 526-532.	0.6	30
27	The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer. European Journal of Cancer, 1997, 33, 1572-1577.	1.3	46
28	High rate of MDR â€1 and heterogeneous pattern of MRP expression without gene amplification in endometrial cancer. International Journal of Cancer, 1995, 63, 798-803.	2.3	19
29	Tumor Antigens CA 19.9, CA 125, and CEA in Carcinoma of the Uterine Cervix. Gynecologic Oncology, 1995, 57, 205-211.	0.6	59